Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06851221

Enrollment

Registered

2025-02-28

Start date

2020-08-05

Completion date

2024-03-05

Last updated

2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ewing Sarcoma, Neuroblastoma

Brief summary

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.

Interventions

DIAGNOSTIC_TESTbeta3 expression

the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

0 Years to 18 Years

Healthy volunteers

Inclusion criteria

* diagnosis of Ewing sarcoma or neuroblastoma

Exclusion criteria

* sieropositivity

Design outcomes

Primary

Measure	Time frame
expression of beta3-adrenoreceptor	from enrollment to the performance of the analysis that can take up to 6 weeks

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026